SCRI Development Innovations, LLC
scri.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
179
Active
6
Phase 3
4
Total enrollment
12,327
Pipeline matrix
Showing 13 of 13 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Tocilizumab | — | — | — | — | — | 2 | |
| Elranatamab | — | — | — | — | — | 2 | |
| Lenalidomide | — | — | — | — | — | 5 | |
| Doxil | — | — | — | — | — | 2 | |
| Tucatinib | — | — | — | — | — | 1 | |
| Teclistamab | — | — | — | — | — | 1 | |
| Talquetamab | — | — | — | — | — | 1 | |
| Oral Dexamethasone | — | — | — | — | — | 1 | |
| BMS-986489 | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| fruquintinib | — | — | — | — | — | 1 | |
| FOLFIRI | — | — | — | — | — | 1 | |
| Daratumumab | — | — | — | — | — | 1 |
Next readouts
- 2027-01
- 2027-08
- 2027-11
- 2029-10
- 2032-05
- 2032-11
Top conditions
- Breast Cancer25
- Lung Cancer18
- Multiple Myeloma11
- Metastatic Breast Cancer9
- Non-Small Cell Lung Cancer6
- Prostate Cancer5
- Colorectal Cancer5
- Non Small Cell Lung Cancer5
Frequently asked questions about SCRI Development Innovations, LLC
- How many clinical trials does SCRI Development Innovations, LLC have on ClinicalTrials.gov?
- SCRI Development Innovations, LLC is listed as the lead sponsor on 179 clinical trials in ClinicalTrials.gov, 6 of which are currently active (recruiting, enrolling, or ongoing).
- How many of SCRI Development Innovations, LLC's trials are in Phase 3?
- 4 of SCRI Development Innovations, LLC's trials are in Phase 3, spread across 13 active drug programs.
- What therapeutic areas does SCRI Development Innovations, LLC focus on?
- SCRI Development Innovations, LLC's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Lung Cancer, Multiple Myeloma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer.
- When are SCRI Development Innovations, LLC's next clinical trial readouts?
- SCRI Development Innovations, LLC has 6 upcoming primary-completion readouts tracked here; the soonest is “A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)”, expected around 2027-01.